A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis | MicrobiomeTrials

← Back to trials

NCT06215716

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2023-12-01Est. Completion: 2033-02

Enrollment target: 1,650 participants

Locations

Akero Clinical Study Site, Birmingham, Alabama, United States
Akero Clinical Study Site, Dothan, Alabama, United States
Akero Clinical Study Site, Chandler, Arizona, United States
Akero Clinical Study Site, Flagstaff, Arizona, United States
Akero Clinical Study Site, Peoria, Arizona, United States
Akero Clinical Study Site, Tucson, Arizona, United States
Akero Clinical Study Site, Tucson, Arizona, United States
Akero Clinical Study Site, Tucson, Arizona, United States
Akero Clinical Study Site, Tucson, Arizona, United States
Akero Clinical Study Site, Conway, Arkansas, United States
Akero Clinical Study Site, Jonesboro, Arkansas, United States
Akero Clinical Study Site, Little Rock, Arkansas, United States
Akero Clinical Study Site, North Little Rock, Arkansas, United States
Akero Clinical Study Site, Chula Vista, California, United States
Akero Clinical Study Site, Coronado, California, United States
Akero Clinical Study Site, Escondido, California, United States

Other microbiome trials you might be interested in

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHPhase 3Recruiting

Non-alcoholic Fatty Liver Disease

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis…

Chandler, United StatesEst. completion Mar 29, 2028

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHPhase 3Recruiting

Non-alcoholic Fatty Liver Disease

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH …

Arcadia, United StatesEst. completion Mar 24, 2028

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.